Search results for "trials"

showing 10 items of 966 documents

'Tell Us Only What You Know': Evidentiality in the Discourse of Participants in Spanish Trials

2019

El objetivo de esta propuesta es explorar el uso de la evidencialidad en los juicios españoles y su relación con las convenciones del género y los roles de los participantes en estos eventos discursivos. Para ello, basamos nuestro estudio en un análisis cuantitativo-cualitativo de un corpus transcrito de ensayos orales en español. La evidencialidad es una categoría semántico-funcional que incluye dispositivos lingüísticos que marcan la fuente de información detrás de las declaraciones del hablante. El marcado explícito de la fuente no es obligatorio en español; sin embargo, en géneros específicos (legal, parlamentario y académico), se convierte en una poderosa herramienta argumentativa para…

Linguistics and LanguageArgumentativelegal discourseLogical reasoningmedia_common.quotation_subjectevidentialityPragmaticscomputer.software_genreSemanticsLanguage and LinguisticsLinguisticsComputer Science ApplicationsNegotiationLiteratura espanyolaScripting languageEvidentialitySpanish trialsComputational linguisticsPsychologycomputerattenuationmedia_common
researchProduct

Atenuación en el discurso de los participantes no profesionales de los juicios orales. ¿Un caso de lenguaje débil?

2020

El objetivo de este artículo es estudiar la manera en que se manifiesta la atenuación en los participantes no profesionales de los juicios orales. Tradicionalmente, se ha vinculado el empleo de recursos relacionados con la atenuación (como los hedges o las fórmulas de cortesía) con el lenguaje débil, pues las personas que usan estos recursos en su declaración limitan su compromiso con lo dicho y son percibidas como menos creíbles y menos inteligentes (Erickson, Lind, Johnson & O'Barr, 1978). No obstante, tras analizar un corpus de 12 juicios orales españoles pertenecientes al juzgado de lo penal, se ha comprobado que el uso de estos y otros recursos que se asocian con la atenuación pueden p…

Linguistics and LanguageLiterature and Literary TheoryMitigationPolitenesslenguaje débilmedia_common.quotation_subjectpowerless speechAtenuacióntrialsAnàlisi del discursdiscurso débilpowerless languageLanguage and LinguisticsArgumentation theoryargumentaciónjuicios oralesargumentationCriminal courtPsychologySocial psychologymedia_common
researchProduct

Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis

2003

Abstract Background & aims: Emergency sclerotherapy is used as a first-line therapy for variceal bleeding in cirrhosis, although pharmacologic treatment stops bleeding in most patients. We performed a meta-analysis comparing emergency sclerotherapy with pharmacologic treatment. Methods: MEDLINE (1968–2002), EMBASE (1986–2002), and the Cochrane Library (2002;4) were searched to retrieve randomized controlled trials comparing sclerotherapy with vasopressin (± nitroglycerin), terlipressin, somatostatin, or octreotide for variceal bleeding in cirrhosis. Outcome measures were failure to control bleeding, rebleeding, blood transfusions, adverse events, and mortality. Results: Fifteen trials were …

Liver CirrhosisEmergency Medical ServicesVariceal bleedingmedicine.medical_specialtyCirrhosisVasopressinsmedicine.medical_treatmentOctreotideLypressinCochrane LibraryEsophageal and Gastric VaricesOctreotideGastroenterologyHemostaticslaw.inventionRandomized controlled triallawVasoactiveInternal medicineSclerotherapySclerotherapyHumansVasoconstrictor AgentsMedicineAdverse effectRandomized Controlled Trials as TopicHepatologybusiness.industryGastroenterologymedicine.diseaseHormonesSurgeryAnesthesiaMeta-analysisAcute DiseaseTerlipressinVaricesGastrointestinal HemorrhageSomatostatinbusinessTerlipressinmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Prevention of Hepatocellular Carcinoma

2005

The accuracy and the reliability of well-recognized clinical, virologic, histologic, and molecular risk factors for HCC are still insufficient; thus, accurate risk prediction of developing cancer in individual patients remains an elusive goal. Future directions in chemprevention of HCC will be on the development of molecular risk models and of new chemopreventive agents. The design of targeted molecular therapies may need to be tailored to the specific molecular phenotype of a specific HCC. Studies examining multiple genes and proteins (genomics and proteomics) in the same HCCs will be required to evaluate this possibility thoroughly. In the setting of primary prevention, the epidemiologic …

Liver CirrhosisMaleadefovirOncologymedicine.medical_specialtyCarcinoma HepatocellularAntiviral AgentsRisk AssessmentSensitivity and SpecificityGastroenterologyHepatitis B Chronicpolyprenoic acidretinoidInternal medicinemedicineHumansMass Screeningantineoplastic agentReliability (statistics)Randomized Controlled Trials as TopicHepatologybusiness.industryLiver NeoplasmsCancerinterferonHepatitis C ChronicPrognosismedicine.diseaseSurvival AnalysisPrimary Preventionhepatitis C vaccineHepatocellular carcinomaFemaleInterferonslamivudinebusinesshepatitis B vaccineClinics in Liver Disease
researchProduct

Should cirrhosis change our attitude towards treating non-hepatic cancer?

2011

Cirrhosis is a major cause of morbidity and mortality and is the end stage of any chronic liver disease. Cancer, a leading cause of death worldwide, is a growing global health issue. There are limited data in the literature on the incidence, prevalence and management of non-hepatic cancers (NHC) in cirrhotic patients. The aim of this brief review was to underline the main concerns, pitfalls and warnings regarding practice for these patients. Survival of patients with compensated cirrhosis is significantly longer than that of decompensated cirrhosis and patients with NHC and in Child-Pugh class C should not be candidates for cytotoxic chemotherapy. It is important before starting cytotoxic c…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisAntineoplastic AgentsComorbidityChronic liver diseaseGastroenterologyLiver diseaseInternal medicineCause of DeathNeoplasmsmedicineHumansIntensive care medicineSurvival rateCause of deathHepatologybusiness.industryPatient SelectionCancerProfessional Practicemedicine.diseasechemotherapy – cirrhosis – hepatotoxicity – non-hepatic cancerClinical trialSurvival RateClinical Trials Phase III as TopicPortal hypertensionFemaleChemical and Drug Induced Liver InjurybusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis

2022

Background: The aims of this study were to quantify the histological improvement and its risk factors in patients with NASH enrolled in the placebo arms of randomized controlled trials (RCTs), and to indirectly compare the effect of several investigational drugs for NASH on validated histological outcomes.Data synthesis: A comprehensive search was conducted to detect phase 2 and 3 RCTs comparing pharmacological interventions in patients with NASH. According to Food and Drug Administra-tion (FDA) recommendations, primary outcomes included: 1) NASH resolution without wors-ening of fibrosis; 2) At least 1-point reduction in fibrosis without worsening of NASH. Meta -analysis and meta-regression…

Liver CirrhosisNutrition and DieteticsLiverNon-alcoholic Fatty Liver DiseaseEndocrinology Diabetes and MetabolismNetwork Meta-AnalysisMeta-analysis NASH Network meta-analysisMedicine (miscellaneous)HumansVitamin EDrugs InvestigationalCardiology and Cardiovascular MedicineRandomized Controlled Trials as Topic
researchProduct

Treatment of hepatitis C: critical appraisal of the evidence

2005

Chronic hepatitis C virus infection is currently the most common cause of end stage liver disease worldwide. Although the conclusions of the last National Institutes of Health Consensus Development Conferences on Hepatitis C have recently been published, several important issues remain unanswered. This paper reviews the available data using an evidence-based approach. Current evidence is sufficient to recommend IFN treatment for all patients with acute hepatitis. A later initiation of therapy yields the same likelihood of response as early treatment. A daily induction dose during month 1 is the best treatment option. The current gold standard of efficacy for treatment-naive patients with ch…

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularCirrhosisInterferon alpha-2Antiviral AgentsPolyethylene Glycolschemistry.chemical_compoundMaintenance therapyPegylated interferonInternal medicinemedicineHumansPharmacology (medical)Randomized Controlled Trials as TopicPharmacologybusiness.industrycombination treatment hepatitis C histological benefit meta-analysis pegylated interferonRibavirinLiver NeoplasmsInterferon-alphaGeneral MedicineHepatitis CHepatitis C Chronicmedicine.diseaseHepatitis CRecombinant ProteinschemistryTolerabilityHepatocellular carcinomaMeta-analysisAcute DiseaseImmunologybusinessmedicine.drug
researchProduct

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.

2001

Abstract Background/Aims : To evaluate by meta-analysis of available literature whether interferon (IFN) reduces the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) or hepatitis C virus (HCV)-related Child A cirrhosis. Methods : Three randomized controlled trials and 15 nonrandomized controlled trials, including 4614 patients and comparing IFN to no treatment, were selected. Data on the incidence of HCC in IFN treated and untreated patients were extracted from each study. Meta-analysis by the DerSimonian and Laird risk difference (RD) method was used to pool observations. Results : A different incidence of HCC between treated and untreated cirrhotic pati…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma HepatocellularHepatocellular carcinoma; Interferon; Viral cirrhosis;Hepatitis C virusmedicine.disease_causeGastroenterologyAntiviral AgentsInternal medicinemedicineCarcinomaHumansHepatitis B virusClinical Trials as TopicHepatologybusiness.industryIncidence (epidemiology)Liver Neoplasmsmedicine.diseaseHepatitis Cdigestive system diseasesHepatocellular carcinomaImmunologyViral diseaseInterferonsbusinessViral hepatitisJournal of hepatology
researchProduct

Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized contr…

2009

Radiofrequency thermal ablation (RF) and percutaneous ethanol injection (PEI) have been employed in the treatment of small hepatocellular carcinoma (HCC) as curative treatments. The aim of the study was to review the available evidence comparing RF to PEI for small HCC.Cochrane, MEDLINE, CANCERLIT, and ENBASE databases were used.randomized clinical trials evaluating RF vs. PEI. Data were extracted from each randomized controlled trial (RCT). Primary outcomes were overall survival and local recurrence. Meta-analysis software was used and risk differences (RDs) and their 95% confidence intervals and Q-test for heterogeneity were calculated.Five RCTs were identified including 701 patients. The…

Liver Cirrhosismedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentThermal ablationUrologyCatheter ablationInjections Intralesionallaw.inventionRandomized controlled triallawmedicineHumansSurvival rateRandomized Controlled Trials as TopicHepatologyEthanolbusiness.industryLiver NeoplasmsGastroenterologymedicine.diseaseSurgerySurvival RateTreatment OutcomeMeta-analysisHepatocellular carcinomaCatheter AblationSolventsPercutaneous ethanol injectionbusinessThe American journal of gastroenterology
researchProduct

Traditional Chinese Medicine (TCM) for fibrotic liver disease: Hope and hype

2014

Liver Cirrhosismedicine.medical_specialtyCirrhosisMEDLINEHolistic HealthTraditional Chinese medicineHolistic healthGastroenterologyHepatitisLiver diseaseFibrosisInternal medicineChinese traditionalHBVmedicineHumansMedicine Chinese TraditionalIntensive care medicineInflammationHepatitisClinical Trials as TopicHerbHepatologybusiness.industryNASHmedicine.diseaseFibrosisTCMCirrhosisLiverHCVCollagenAntifibroticbusinessDrugs Chinese HerbalJournal of Hepatology
researchProduct